Drug intelligence / Profile preview

SHEP-005

Development stage: Preclinical
Lead developer: Shepherd Therapeutics

Overview

SHEP-005 is a preclinical therapeutic candidate being developed by Shepherd Therapeutics for the treatment of several rare and aggressive cancers, including adenoid cystic carcinoma, adrenocortical carcinoma, carcinoid tumors, cholangiocarcinoma, esophageal cancer, and Ewing's sarcoma. The drug was identified or developed using Shepherd's DELVE platform, which integrates multi-omic data to discover therapeutic opportunities for rare diseases. As of the current reporting, SHEP-005 is in the IND-enabling or preclinical stage of development. Specific details regarding its molecular target, mechanism of action, and chemical modality have not been publicly disclosed by the developer.

Beyond the preview

Go deeper on SHEP-005.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SHEP-005.

Explore the full profile